# TG Therapeutics

TG Therapeutics is an Asset Manager based in Morrisville, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Morrisville, United States
- **Region:** North America
- **Address:** Morrisville, NC, United States
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** tgtherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/tg-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

TG Therapeutics launched in 2012 under the direction of Executive Chairman and CEO Michael S. Weiss, a veteran biotech executive who previously built and sold Keryx Biopharmaceuticals. The company is not a family office or fund — it is a fully integrated commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina. Its core identity rests on developing novel treatments for B-cell diseases. The company took an unconventional path by advancing an anti-CD20 monoclonal antibody, ublituximab, through pivotal trials while simultaneously holding a portfolio of PI3K-delta and CK1-epsilon inhibitors. The firm's strategy focuses wholly on acquiring, developing, and commercializing therapeutic candidates for hematologic malignancies and autoimmune diseases. Its primary asset, Briumvi (ublituximab-xiiy), received FDA approval in December 2022 for relapsing forms of multiple sclerosis. TG Therapeutics launched the drug commercially in early 2023, competing directly with established anti-CD20 therapies like Ocrevus and Kesimpta. The company's pipeline also includes TG-1701, a BTK inhibitor, and TG-1801, an anti-CD47/CD19 bispecific antibody, under clinical investigation for non-Hodgkin's lymphoma. Its geographic footprint concentrates in the United States, where it manages its own specialty pharmaceutical sales force, with commercialization agreements covering other territories. TG Therapeutics operates from its single headquarters in North Carolina and has publicly shifted its resource allocation toward the Briumvi commercial launch following the voluntary withdrawal of its PI3K-delta inhibitor, Ukoniq, from oncology markets in 2022. This decision followed an FDA clinical hold and a subsequent strategic pivot that refocused the entire enterprise on the multiple sclerosis market. The company remains without a large-cap pharmaceutical partner for its lead asset, keeping US commercialization rights fully in-house — an uncommon structural choice that concentrates operational complexity but preserves margin. Structurally, TG Therapeutics is a publicly traded C-corporation dependent on drug sales and secondary equity offerings rather than the limited-partner commitments typical of a family office or investment fund model. The firm's governance sits under a board led by Weiss, who retains significant executive authority over both clinical pipeline prioritization and commercial execution. There is no intergenerational wealth transfer story, no foundation structure managing donor-advised funds — this is a biotechnology company whose future rests on delivering quarterly Briumvi prescription growth.

## Sectors

- Biotechnology

## People

- Michael S. Weiss — Executive Chairman and CEO
- Sean A. Power — Chief Financial Officer

## Questions

### What generates revenue for TG Therapeutics, and who manages the drug's commercial rollout?

Revenue comes from US net sales of Briumvi (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for relapsing multiple sclerosis in December 2022. Michael Weiss leads the overall commercial strategy, supported by an in-house specialty sales force responsible for engaging neurologists across the United States. TG Therapeutics declined to partner Briumvi commercially in the US, retaining full distribution rights.

### Was the pivot away from oncology a set-back or a deliberate strategic necessity for the firm?

It was a forced necessity. The firm voluntarily withdrew its PI3K-delta inhibitor, Ukoniq, from the market in 2022 and terminated related oncology clinical trials after the FDA placed a clinical hold over safety concerns. Management rapidly redirected all available resources toward the Briumvi launch, effectively repositioning TG Therapeutics from a dual-focus oncology-and-autoimmune enterprise into an MS-focused commercial biotech.

### Who executes investment or capital-allocation decisions at TG Therapeutics?

Capital allocation is an executive-level function led by CEO Michael Weiss and CFO Sean Power. As a publicly traded biotech, decisions center on clinical-trial funding, manufacturing scale-up for Briumvi, and commercial infrastructure rather than portfolio allocation across external assets or funds. The company relies on periodic equity offerings for financing — unlike a family office or fund, it does not make financial investments in unrelated third-party GPs.

## Related profiles

- [Rayonier](https://altss.com/profile/rayonier-inc)
- [Klarna Group plc](https://altss.com/profile/klarna-group-plc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/tg-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology